

NTRK3 dimers trans-autophosphorylate

Orlic-Milacic, M., Tsoulfas, P.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of <u>Creative Commons Attribution 4.0 International (CC BY 4.0)</u>
<u>License</u>. For more information see our <u>license</u>.

03/05/2024

https://reactome.org

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142.
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467.
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655.
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology, 14*, e1005968.

Reactome database release: 88

This document contains 1 reaction (see Table of Contents)


https://reactome.org Page 2

NTRK3 dimers trans-autophosphorylate 7

Stable identifier: R-HSA-9034714

Type: transition

Compartments: plasma membrane, cytosol



NTRK3 (TRKC), activated by NTF3 binding, trans-autophosphorylates on tyrosine residues in the intracellular domain (Urfer et al. 1995, Yuen and Mobley 1999, Huang and Reichardt 2001). Tyrosine residue Y516 of NTRK3 was directly shown to be autophosphorylated (Werner et al. 2014), while tyrosine residues Y705, Y709, Y710 and Y834 are predicted to be phosphorylated based on sequence similarity with NTRK2 (TRKB).

Literature references

Urfer, R., Parada, LF., Shelton, DL., O'Connell, L., Presta, LG., Tsoulfas, P. (1995). An immunoglobulin-like domain determines the specificity of neurotrophin receptors. *EMBO J.*, 14, 2795-805. *¬*

Yuen, EC., Mobley, WC. (1999). Early BDNF, NT-3, and NT-4 signaling events. Exp. Neurol., 159, 297-308.

Reichardt, LF., Huang, EJ. (2001). Neurotrophins: roles in neuronal development and function. *Annu. Rev. Neurosci.*, 24, 677-736.

Iyer, R., Goldmuntz, E., Simpson, AM., Brodeur, GM., Latney, B., Werner, P. et al. (2014). Mutations in NTRK3 suggest a novel signaling pathway in human congenital heart disease. *Hum. Mutat.*, 35, 1459-68. *▶*

Editions

2018-01-02	Authored	Orlic-Milacic, M.
2018-05-09	Edited	Orlic-Milacic, M.
2018-05-09	Reviewed	Tsoulfas, P.